High-yield points
- Gorlin = PTCH1 or SUFU (SHH pathway). The gene sets the medulloblastoma risk: PTCH1 under 2%; SUFU up to 20 times higher. Median age at medulloblastoma in SUFU carriers is 1.5 years .
- Screen SUFU carriers with brain MRI from birth to 5. PTCH1 carriers do not need medulloblastoma screening .
- Infant desmoplastic or nodular SHH medulloblastoma: test the germline. SUFU children often lack classic Gorlin features but have macrocrania .
- Avoid radiotherapy. Radiation-sparing chemotherapy gives excellent survival. Radiation brings second malignancies , including basal cell carcinomas in the field (see caveats).
- SUFU medulloblastoma relapses locally more often .
Gorlin syndrome (nevoid basal cell carcinoma syndrome, or basal cell nevus syndrome) is a cancer-predisposition syndrome. It is caused by a germline pathogenic variant in a Sonic Hedgehog (SHH) pathway gene, PTCH1 or SUFU .
Its tumors fall into two groups :
- the main tumor types:
- basal cell carcinomas;
- odontogenic keratocysts of the jaw;
- medulloblastoma;
- others:
- meningiomas;
- ovarian and cardiac fibromas;
- sarcomas.
For the neurosurgeon, two decisions depend on the gene:
- SHH medulloblastoma in a very young child: whether to screen for it;
- Radiotherapy: how to avoid it .
Genetics: why the gene matters
- PTCH1 causes most Gorlin syndrome.
- Medulloblastoma risk is under 2%: 2 of 115 carriers (1.7%) .
- SUFU also causes classic Gorlin syndrome.
- Medulloblastoma risk is up to 20 times higher than with PTCH1. Each SUFU family in the original report had one medulloblastoma .
- Older estimates of a 5% medulloblastoma risk in Gorlin syndrome blurred this gene difference .
- SUFU carriers in detail (172 patients) :
- 68% developed at least one tumor, and medulloblastoma was the commonest (86 patients);
- median age at medulloblastoma diagnosis was 1.5 years;
- in relatives, the cumulative medulloblastoma risk by age 50 was 13.3%;
- the spectrum by age: medulloblastoma before 5, gonadal tumors in adolescence, basal cell carcinoma and meningioma in adulthood.
- The jaw clue: SUFU families in the first report had no odontogenic jaw keratocysts .
- Many SUFU children with medulloblastoma do not meet clinical Gorlin criteria.
- In a French series, 20 of 22 had macrocrania, but only 5 met the diagnostic criteria .
Medulloblastoma in Gorlin syndrome
- The tumor: typically SHH-activated, desmoplastic/nodular or with extensive nodularity (MBEN), in children under about 3 years .
- In the German HIT-MED cohort (16 patients), age at diagnosis was 0.65–3.41 years. Every tumor tested was SHH-activated.
- Treatment:
- maximal safe resection;
- chemotherapy designed to avoid craniospinal radiotherapy .
- Results with radiation-sparing chemotherapy (HIT-MED):
- no patient received radiotherapy in initial treatment;
- 10-year overall survival 90% (PTCH1) and 100% (SUFU), not different from other young SHH medulloblastomas .
- SUFU-associated tumors can do worse (French series of 22) :
- 5-year progression-free survival 42%, overall survival 66%;
- frequent local relapses (8 of 22);
- second malignancies (6 in 4 patients).
- Why avoid radiation: treated patients need prolonged, thorough follow-up because of secondary malignancies .
- In Gorlin syndrome, irradiated skin develops multiple basal cell carcinomas in the field (see caveats).
- Meningiomas occur in both PTCH1 and SUFU carriers .
Surveillance (SIOPE 2021 recommendations)
- Brain MRI for medulloblastoma: repeated imaging from birth to age 5, for SUFU carriers only.
- Brain MRI for meningioma: offered to both PTCH1 and SUFU carriers.
- Skin examination for basal cell carcinoma: from age 10 (PTCH1) and age 20 (SUFU).
- Odontogenic keratocysts: dental examination from age 2, and an annual orthopantogram from about age 8, for PTCH1 carriers only.
- Ovarian fibromas: pelvic ultrasound for both.
- Imaging choice: prefer MRI and limit CT and radiographs where possible, because of radiation sensitivity (see caveats).
Recognizing Gorlin syndrome
- Clinical criteria (international consensus) combine major and minor features :
- early or multiple basal cell carcinomas;
- jaw keratocysts;
- palmar or plantar pits;
- lamellar falx calcification;
- medulloblastoma;
- first-degree relative;
- rib anomalies;
- macrocephaly;
- cleft lip or palate;
- other skeletal and ocular anomalies.
- Practical rule: a child under 3 with a desmoplastic or nodular SHH medulloblastoma should have germline PTCH1 and SUFU testing, even without other features .
Related topics
- Medulloblastoma: Molecular Classification and Prognosis: SHH subgroup biology and treatment.
- Meningioma in Children: meningiomas occur in PTCH1 and SUFU carriers.
- Li-Fraumeni Syndrome: the contrast: radiotherapy helps in TP53 medulloblastoma.
References
- Guerrini-Rousseau L, Smith MJ, Kratz CP, et al. Current recommendations for cancer surveillance in Gorlin syndrome: a report from the SIOPE host genome working group (SIOPE HGWG). Fam Cancer 2021;20(4):317–325. doi:10.1007/s10689-021-00247-z. PMID 33860896. verified
- Smith MJ, Beetz C, Williams SG, et al. Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol 2014;32(36):4155–4161. doi:10.1200/JCO.2014.58.2569. PMID 25403219. verified
- Bree AF, Shah MR; BCNS Colloquium Group. Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS). Am J Med Genet A 2011;155A(9):2091–2097. doi:10.1002/ajmg.a.34128. PMID 21834049. verified
- Guerrini-Rousseau L, Masliah-Planchon J, Waszak SM, et al. Cancer risk and tumour spectrum in 172 patients with a germline SUFU pathogenic variation: a collaborative study of the SIOPE Host Genome Working Group. J Med Genet 2022;59(11):1123–1132. doi:10.1136/jmedgenet-2021-108385. PMID 35768194. verified
- Guerrini-Rousseau L, Dufour C, Varlet P, et al. Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis. Neuro Oncol 2018;20(8):1122–1132. doi:10.1093/neuonc/nox228. PMID 29186568. verified
- Kloth K, Obrecht D, Sturm D, et al. Defining the spectrum, treatment and outcome of patients with genetically confirmed Gorlin syndrome from the HIT-MED cohort. Front Oncol 2021;11:756025. doi:10.3389/fonc.2021.756025. PMID 34888241. verified
Verification (2026-11-17):
- Each reference's authors, title, journal, year, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts.
Caveats:
- The following come from the full text or standard teaching, not the cited abstracts:
- the list of diagnostic features (reference 3's abstract does not list them);
- basal cell carcinomas in radiation fields;
- minimizing CT and radiographs;
- testing every infant SHH medulloblastoma.
- Reference 3 is cited for the existence of consensus criteria, and its full list should be checked before teaching specifics.
- The figure is an original schematic.